Evidence map›Paper›PMID 34677878›Full record

ArticleAmerican journal of hematology2022

Congenital X-linked neutropenia with myelodysplasia and somatic tetraploidy due to a germline mutation in SEPT6.

Raffaele Renella, Katelyn Gagne, Ellen Beauchamp, Jonathan Fogel, Aleksej Perlov, Mireia Sola, Thorsten Schlaeger, Inga Hofmann, Akiko Shimamura, Benjamin L Ebert and 12 more

Open access · bronzeAbstract readCase Reports
In one paragraph

Article in American journal of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Deep Learning in Hematology: From Molecules to Patients.Clinical hematology international · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 3 institutions in 2 countries.

Raffaele RenellaPediatric Hematology-Oncology Research Laboratory, Lausanne University Hospital, Switzerland.ORCID 0000-0002-5041-2308
Katelyn GagneDivision of Hematology-Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Ellen BeauchampDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Jonathan FogelDivision of Hematology-Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Aleksej PerlovDivision of Hematology-Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Mireia SolaInstitute for Protein Innovation, Boston, Massachusetts, USA.
Thorsten SchlaegerDivision of Hematology-Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Inga HofmannDivision of Hematology-Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Akiko ShimamuraDivision of Hematology-Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-4683-9958
Benjamin L EbertDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Klaus Schmitz-AbeDivision of Newborn Medicine, Department of Pediatrics, Boston Children's Hospital, Boston, Massachusetts, USA.
Kyriacos MarkianosThe Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.
Kristi MurphyThe Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.
Liang SunThe Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.
Shira RockowitzThe Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA.
Piotr SlizDivision of Molecular Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Dean R CampagnaDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Timothy A SpringerProgram in Cellular & Molecular Medicine, Boston Children's Hospital, Boston, Massachusetts, USA.
Christopher BahlDivision of Hematology-Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0002-3652-3693
Suneet AgarwalDivision of Hematology-Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Mark D FlemingDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-0948-4024
David A WilliamsDivision of Hematology-Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-7057-6863
Boston Children's Hospital · USHarvard University · USInstitute for Protein Innovation · US

Funding

Translational Studies of Inherited Marrow Failure and Myelodysplastic SyndromesR24DK099808 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ABKOWITZ, JANIS L, EBERT, BENJAMIN LEVINE · 2013 to 2017
$8.2M
Systems Biology of Bone Marrow Failure and MDS for Precision MedicineRC2DK122533 · NIDDK · BOSTON CHILDREN'S HOSPITAL · PI FIGUEROA, MARIA EUGENIA, FLEMING, MARK D · 2019 to 2023
$6.4M
NIDDK NIH HHS R24 DK099808NIDDK NIH HHS RC2 DK122533
6 · The paper itself

Abstract

Septins play key roles in mammalian cell division and cytokinesis but have not previously been implicated in a germline human disorder. A male infant with severe neutropenia and progressive dysmyelopoiesis with tetraploid myeloid precursors was identified. No known genetic etiologies for neutropenia or bone marrow failure were found. However, next-generation sequencing of germline samples from the patient revealed a novel, de novo germline stop-loss mutation in the X-linked gene SEPT6 that resulted in reduced SEPT6 staining in bone marrow granulocyte precursors and megakaryocytes. Patient skin fibroblast-derived induced pluripotent stem cells (iPSCs) produced reduced myeloid colonies, particularly of the granulocyte lineage. CRISPR/Cas9 knock-in of the patient's mutation or complete knock-out of SEPT6 was not tolerated in non-patient-derived iPSCs or human myeloid cell lines, but SEPT6 knock-out was successful in an erythroid cell line and resulting clones revealed a propensity to multinucleation. In silico analysis predicts that the mutated protein hinders the dimerization of SEPT6 coiled-coils in both parallel and antiparallel arrangements, which could in turn impair filament formation. These data demonstrate a critical role for SEPT6 in chromosomal segregation in myeloid progenitors that can account for the unusual predisposition to aneuploidy and dysmyelopoiesis.

Indexed as

Germ-Line MutationCell LineCells, CulturedGenetic Diseases, X-LinkedHumansInfant, NewbornMaleMyelodysplastic SyndromesNeutropeniaSeptinsTetraploidySEPTIN6 protein, humanSeptins

Identifiers

PMID34677878
PMCPMC8671325
OpenAlexW3205685115

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.